1 week ago
ENHERTU is a specifically engineered HER2 directed antibody drug conjugate (ADC) being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The approval was granted under the FDA's Real-Time Oncology Review (RTOR) ...
Read more at Business Wire
The FDA has approved Enhertu (fam-trastuzumab-deruxtecan-nxki) for adults with unresectable or metastatic HER2-low breast cancer.
Read more at Monthly Prescribing Reference
The U.S. Food and Drug Administration has approved the drug trastuzumab-deruxtecan for patients with the HER2-low breast cancer subtype.
Read more at Health Digest
On Friday, the U.S. Food and Drug Administration (FDA) approved trastuzumab-deruxtecan—sold under the brand name Enhertu—for the treatment of patients with unresectable or metastatic HER2-low breast cancer. Administered through IV infusion, ...
Read more at Inside Precision Medicine
FDA approves AstraZeneca and Daiichi Sankyo's Enhertu as first targeted treatment specifically for patients with unresectable or metastatic HER2-low breast cancer.
Read more at pharmaphorum
News in business Category
Signal is, more often than not, synonymous with privacy and security. After all, its encryption protocol not only protects its own chats with end-to-end encryption, but it's also featured on messaging apps like WhatsApp, which are used by billions of ...
Read more at Android Police
Share this article. Facebook · Twitter · Whatsapp · Email; Print; Save. ASX 200 rises on BHP profit surge; Challenger smashed; Tassal accepts $1.7bn bid. By David Rogers. and Valerina Changarathil. and Matt Bell. 6:55AM August 16, 2022; Comments ...
Read more at The Australian